| Literature DB >> 35859440 |
Anuradha S Tripathy1, Diptee Trimbake1, Poonam V Suryawanshi2, Srikanth P Tripathy2, Yogesh K Gurav3, Varsha A Potdar4, Manohar L Chaudhary4, Prachi Athavale5, Nitin D Mokashi6, Sudhir D Patsute7, Arjun L Kakrani2, Priya Abraham8.
Abstract
Background & objectives: The COVID-19 disease profile in Indian patients has been found to be different from the Western world. Changes in lymphocyte compartment have been correlated with disease course, illness severity and clinical outcome. This study was aimed to assess the peripheral lymphocyte phenotype and subset distribution in patients with COVID-19 disease from India with differential clinical manifestations.Entities:
Keywords: Asymptomatic; SARS-CoV-2; lymphocyte subset; mild symptomatic; moderate +severe patients; recovered individuals
Mesh:
Substances:
Year: 2022 PMID: 35859440 PMCID: PMC9552374 DOI: 10.4103/ijmr.IJMR_453_21
Source DB: PubMed Journal: Indian J Med Res ISSN: 0971-5916 Impact factor: 5.274
Fig. 1(A) Gating strategy for the enumeration of natural killer (NK) and natural killer T-like (NKT-like) cells in different study groups. Lymphocyte gate was recognized by forward scatter (FSC) & side scatter (SSC). Further, the CD3 negative cells from this population were screened for CD56+ expression to identify the NK cells and were identified as CD3-CD56+ and NKT-like (NKT-like) cells were CD3+CD56+. (B) Gating strategy for the enumeration of B and memory B cells in different study groups. B cells from lymphocytes were identified with the help of CD19 expression. For further differentiation, expression of CD27 was considered as memory B cells.
Demographic and baseline characteristics of patients with SARS-CoV-2 infection and uninfected controls
| Parameters Characteristics | Study participants | ||||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Asymptomatic | Mild symptomatic | Moderate+severe | Recovered | Uninfected controls | |||
| Study population (n) | 53 | 36 | 30 | 40 | 56 | ||
| Male | 31 | 24 | 19 | 23 | 34 | ||
| Female | 22 | 12 | 11 | 17 | 22 | ||
| Sex ratio (male: female) | 1.4 | 2 | 1.7 | 1.35 | 1.54 | ||
| Age (yr), median (range) | 32 (12-79) | 38 (15-75) | 51 (29-74) | 38 (18-70) | 27 (18-47) | ||
| Parameters Signs and symptoms | NA | Positive cases | 95% CI (range) | Positive cases | 95% CI (range) | NA | NA |
|
| |||||||
| Fever (97.1-101 F) | 21 | 58.33 (42-74) | 28 | 93 (84-100) | |||
| Cough | 22 | 61.11 (45-77) | 22 | 73 (57-89) | |||
| Sore throat | 13 | 36.11 (20-51) | 10 | 33 (16-50) | |||
| Breathing difficulty | 7 | 19.44 (6-32) | 28 | 93 (84-100) | |||
| Body ache | 6 | 16.67 (4-28 | 22 | 73 (57-89) | |||
| Headache | 1 | 2.78 (0-8) | 12 | 4 (22-57) | |||
| Diarrhoea | 1 | 2.78 (0-8) | 4 | 13 (1.1-25) | |||
| Nasal discharge | 9 | 25 (10-39) | 0 | 0 | |||
| Nausea vomiting | 0 | 0 | 8 | 26 (10-42) | |||
| Dysuria | 0 | 0 | 2 | 6 (0-15) | |||
| Abdominal pain | 0 | 0 | 3 | 10 (0-20) | |||
| Anosmia | 0 | 0 | 4 | 13 (1-25) | |||
| Loss of smell and taste | 0 | 0 | 9 | 30 (13-43) | |||
| Post onset days of illness, median (range) | NA | 7 (0-17) | 6 (1-15) | 45-60* | NA | ||
| Chronic medical illness/comorbidities | NA | NA | Positive/total number of cases | 95% CI (range) | NA | NA | |
|
| |||||||
| Condition tuberculosis | 1 | 3 (0-9) | |||||
| Diabetes | 12 | 40 (22-57) | |||||
| Hypertension | 14 | 46 (28-64) | |||||
| Heart disease | 1 | 3 (0-9) | |||||
| Cancer | 0 | 0 | |||||
| COPD | 0 | 0 | |||||
| Liver failure | 0 | 0 | |||||
| Dialysis | 0 | 0 | |||||
| HIV | 0 | 0 | |||||
| Kidney disease | 0 | 0 | |||||
| Sickle cell disease or thalassaemia | 0 | 0 | |||||
| Sepsis | 6 | 20 (5-34) | |||||
| ARDS | 7 | 23 (8-38) | |||||
| ARDS with AKI | 1 | 3.33 (0-9) | |||||
* recovered from mild symptomatic infection; # not applicable. ARDS: acute respiratory distress syndrome; AKI: acute kidney injury; NA: not available; COPD: Chronic obstructive pulmonary disease: Human Immunodeficiency Virus
Comparison of immune cell profiles among patients with asymptomatic, mild symptomatic, severe+moderate infection, recovered individuals from severe acute respiratory syndrome-coronavirus-2 infection and uninfected controls
| Cell type | Asymptomatic (n=53) | Mild symptomatic (n=40) | Moderate+severe (n=30) | Asymptomatic+mild symptomatic (n=89) | Recovered (n=40) | Uninfected controls (n=56) |
|---|---|---|---|---|---|---|
| NK and NKT-like cell profile | ||||||
| CD3-CD56+NK cells | 2.16 (0.1-9.6) | 2.27 (0.2-10.4) | 12.5 (0.5-48.4)*$ | 2.21 (0.1-10.4) | 2.38 (0.7-5.4)@ | 8.25 (1.4-37.6)# |
| CD3+CD56+NKT-like cells | 12.7 (0-65.6) | 9.59 (0-62.4) | 9.93 (1.2-30.7)*$ | 11.4 (0-65) | 4.31 (0.7-12)@ | 7.09 (0-26.14) |
| B cell profile | ||||||
| CD19+B cells | 5.49 (1.5-15.20) | 4.40 (1-13) | NA | 5.05 (1-15.2) | 5.09 (2.4-12.6) | 5.09 (1.6-15.30) |
| CD19+CD27+memory B cells | 8.5 (0-29.2) | 12.9 (1.6-31.4) | NA | 10.3 (0-31.4)#, † | 19.7 (5.4-65.8)*,$ | 1.91 (0.2-11.4)# |
| T cell profile | ||||||
| CD3+CD4+Th cells | 67.0 (46.7-87.8)† | 71.7 (44.3-92.4)† | 59.7 (4.19-86.2)† | 68.9 (44.3-92.4)† | 72.6 (48.8-94.5) | 43.8 (30-65)# |
| CD3+CD8+TcCells | 23.3 (0.2-43.6) | 18.6 (2.9-41.1)† | 19.5 (1.9-67.2) | 21.4 (0.2-43.6) | 19.6 (1.9-48.3) | 25.8 (9.2-40.4) |
| Memory T cell profile | ||||||
| CD3+CD4+CD45RO+memTh | 13.8 (0-84.10)† | 25.8 (0-82.9) | 70.5 (36.1-83.3) | 18.7 (0-84.1)# | 46.4 (0.4-91.7)*,$ | 13.9 (3.4-35.2)# |
| CD3+CD8+CD45RO+mem Tc | 4.95 (0-37.5)† | 10.7 (0-42) | 67.8 (5.57-89.0) | 7.28 (0-42)# | 20.3 (0-51.2)*,$ | 4.15 (0.5-13.5)# |
| Treg profile | ||||||
| CD4+CD25+CD127- | 8.35 (0-19.2) | 8.21 (2.8-18.3) | NA | 8.2 (0-19.2) | 9.65 (5.8-13.4) | 8.62 (3.8-13) |
Percentage of each cell type are represented as mean (range) P values: * P<0.006 compared to asymptomatic; $ P<0.006 compared to mild symptomatic; @ P<0.006 compared to moderate+severe, # P<0.006 compared to recovered; † P<0.006 compared to uninfected controls. Bonferroni’s corrected cut off for P values: NK and NKT-like cell profile-(P<0.004), B cell profile-(P<0.006), T cell profile-(P<0.004), Memory T cell profile-(P<0.006), Tregs profile-(P<0.006) are considered significant. NA: not available
Fig. 2Flowcytometric analysis of NK/NKT-like, B and memory B cells, T cell subsets. PBMCs from 53 asymptomatic, 36 mild symptomatic, 30 (Moderate+Severe) COVID-19 patients, 40 recovered individuals and 56 uninfected controls were stained and acquired on flowcytometer. Vertical scatter plots denote the comparisons of frequencies of immune cells and their subpopulation among different study groups: (A) NK cells and NKT-like cells profile, (B) B and memory B cells profile, (C) T-helper and T-cytotoxic cells profile, (D) Memory Th and Tc cells, Tregs profile. Data are presented as percentage of immune cells out of lymphocytes. The dots represent individual values and bars represent Mean+SD values (P *** <0.0001). ns, not significant
Comparison of immune cell profiles among severe, mild symptomatic, patients not requiting O2 support (asymptomatic+mild symptomatic) and patients requiting O2 support (moderate + severe) patients with SARS-CoV-2 infection
| Cell type | Patients not requiting O2 support (asymptomatic + mild symptomatic [n=89]) | Patients requiting O2 support (moderate + severe [n=30]) | Mild symptomatic (n=36) | Severe (n=15) |
|---|---|---|---|---|
| NK and NKT-like cell profile | ||||
| CD3-CD56+NK cells | 2.21 (0.1-10.4) | 12.5 (0.5-48.4)* | 2.27 (0.2-10.4) | 10.9 (0.57-33)$ |
| CD3+CD56+NKT-like cells | 11.4 (0-65) | 9.93 (1.2-30.7)* | 9.59 (0-62.4) | 11.0 (1.2-30.7)$ |
| T cell profile | ||||
| CD3+CD4+Th cells | 68.9 (44.3-92.4) | 59.7 (4.19-86.2)* | 71.7 (44.3-92.4) | 57.6 (4.1-85.1)$ |
| CD3+CD8+TcCells | 21.4 (0.2-43.6) | 19.5 (1.9-67.2) | 18.6 (2.9-41.1) | 17.3 (5.8-32.2) |
Percentage of each cell type are represented as mean (range). P* <0.05 compared to patients not requiring O2 support; P$ <0.05 compared to mild symptomatic
Fig. 3Flow cytometric analysis of NK/NKT-like, T cell subsets. PBMCs from 89 patients not requiring O2 support (Asymptomatic+ Mild symptomatic), 30 patients requiring O2 support (Moderate+ Severe), 36 mild symptomatic & 15 severe patients were stained and acquired on flowcytometer. Vertical scatter plots denote the comparisons of frequencies of immune cells and their subpopulation among different study groups: (A) CD3-CD56+ NK cells (B) CD3+CD56+ NKT-like cells (C) CD3+CD4+Th (D) CD3+CD8+Tc cells Data are presented as percentage of immune cells out of lymphocytes. The dots represent individual values and bars represent Mean+SD values. (P ***<0.0001).
Fig. 1(E) Gating strategy for the enumeration of T regulatory (Treg) cells (CD4+CD25+ CD127-) in different study groups. Lymphocyte gate was recognized by FSC & SSC. Further, the CD4 positive cells from this population were screened for CD25+CD127- expression to identify (Treg) cells.